For instance, Goldman and collaborators have recently reported on a patient with a stage IB KIF5B-RET fusion-positive NSCLC achieving a complete pathological response on treatment with neoadjuvant selpercatinib, a RET TKI [43]. Here, KIF5B is linked to non-small cell lung carcinoma.